Our Blog

Johnson & Johnson unit ” marketing run amock”?

September 4, 2014

Did Johnson and Johnson’s attempt to convince doctors that metal on metal hip implants were safe amount to “marketing run amok? J&J pushed its pinnacle hip implants, promoting the devices to doctors, plaintiff’s attorney Mark Lanier told jurors yesterday, also that the pinnacle hip implants suffered from design flaws, yet Johnson and Johnson assured doctors they worked “99.9% of the time.”

A large number of patients who had the devices implanted are now having cobalt and chromium material leaching into their bloodstream. J&J is taking the position that the metal in the woman’s ( the plaintiff in the case) body isn’t tied to design flaws, but by the position of the woman’s hips.

You should know that J&J stopped selling the metal on metal hip implant devices in August, 2013 after the FDA indicated it would require device makers to submit new versions of artificial hips for approval. You will likely see news about the artificial hips called Depuy implants.

J and J agreed to put as much as $1 billion and recovery. Medical costs and removal of recalled ASR, hips, the ASR is a different version of hip implant. Many familiar with the orthopedic devices believe J&J did not tell doctors about the failure rate of the devices, instead continued selling them.

Request Your Free Consultation

Get the answers and support you need. Our friendly and experienced Buffalo personal injury lawyers will take the time to understand your case, explain your options, and guide you every step of the way.

Our Practice Areas

Read More Articles

Ohio Court Finds Employment Agreement Unenforceable That Requires Attorney to Return 95% of Fees

Toy Recall

Today, the Pittsburgh Post Gazette reported, that due to high levels of lead, “Team Work Trading” is recalling approximately 1, 400 children’s animal masks and pendants. These masks and pendants were sold from November 2008 – March 2009.

Read Blog
Ohio Court Finds Employment Agreement Unenforceable That Requires Attorney to Return 95% of Fees

Pfizer Agrees to $2.3 Billion Settlement

The CBS Evening News and the AAJ are reporting that Pfizer was hit with $2.3 Billion in fines for for violating federal drug marketing rules. Pfizer was accused of promoting the pain medication Bextra for uses that were not approved.

Read Blog